GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (NAS:ROIV) » Definitions » Earnings per Share (Diluted)

Roivant Sciences (Roivant Sciences) Earnings per Share (Diluted) : $5.20 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences Earnings per Share (Diluted)?

Roivant Sciences's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $6.03. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $5.20.

Roivant Sciences's EPS (Basic) for the three months ended in Dec. 2023 was $6.37. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $5.54.

Roivant Sciences's EPS without NRI for the three months ended in Dec. 2023 was $-0.26. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.22.


Roivant Sciences Earnings per Share (Diluted) Historical Data

The historical data trend for Roivant Sciences's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Earnings per Share (Diluted) Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23
Earnings per Share (Diluted)
-1.18 -1.26 -1.42

Roivant Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.49 -0.05 -0.38 -0.40 6.03

Competitive Comparison of Roivant Sciences's Earnings per Share (Diluted)

For the Biotechnology subindustry, Roivant Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roivant Sciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's PE Ratio falls into.



Roivant Sciences Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Roivant Sciences's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2023 is calculated as

Diluted Earnings Per Share (A: Mar. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1009.03-0)/712.791
=-1.42

Roivant Sciences's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(5096.184-0)/844.462
=6.03

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Roivant Sciences  (NAS:ROIV) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Roivant Sciences Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Roivant Sciences (Roivant Sciences) Business Description

Traded in Other Exchanges
Address
50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
Executives
Eric Venker officer: President & COO C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Keith S Manchester director C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Daniel Allen Gold director 6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119
Qvt Financial Lp 10 percent owner, other: Director by Deputization 888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106
Svf Investments (uk) Ltd 10 percent owner 69 GROSVENOR STREET, LONDON X0 W1K3JP
Rakhi Kumar officer: Chief Accounting Officer C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Performance Llc 10 percent owner 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Sumitomo Chemical Co., Ltd. 10 percent owner 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Softbank Vision Fund L.p. 10 percent owner AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Richard Pulik officer: CFO SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB
Vivek Ramaswamy director C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000

Roivant Sciences (Roivant Sciences) Headlines

From GuruFocus

QVT Financial LP Reduces Stake in Roivant Sciences Ltd

By GuruFocus Research 10-03-2023

Roivant Sciences Announces Change to its Board of Directors

By sperokesalga sperokesalga 02-22-2023